tranScrip
Gareth Dyson is a qualified accountant with over 10 years of experience in commercial finance roles across various multi-national companies. Currently serving as Chief Financial Officer at tranScrip since February 2024, Gareth previously held the same title at Redstor from September 2012 to April 2023, where significant projects included leading the acquisition of Attix5. Additional experience includes roles as Finance Manager at RedPrairie, Senior BPM Analyst at Dun & Bradstreet, Management Accountant at MorphoSys AG, Intercompany Accountant at BG Group, and Credit Assessment at Yell. Gareth Dyson earned a BSc in Physics from the University of Leeds between 1999 and 2002.
This person is not in any offices
tranScrip
tranScrip is a leading contract drug development organisation which supports pharma and biotech companies in the development and lifecycle of medicines. We bring innovative solutions to clients’ global drug development needs. From translational medicine through to registration and post licencing, we deliver both strategic leadership and operational execution of development programmes, covering clinical, regulatory, drug safety, and commercial elements. Our teams of physicians, scientists and regulatory experts, help clients select the most promising drug candidates and bring them to the market. We guide our clients through their decision making from first in man studies to proof of concept and pivotal trials, regulatory submissions and product launches. In the last decade, tranScrip has supported over 250 clients and has been integral to many development programmes and regulatory submissions, bringing products to the market each year across a wide range of therapeutic areas.